Colorectal tumor cell (CRC cell)

Colorectal tumor cells are malignant epithelial cells originating in the colon or rectum, characterized by dysregulated proliferation and evasion of programmed cell death [10]. Their transformation typically follows the adenoma-carcinoma sequence, driven by somatic mutations in genes such as APC, KRAS, TP53, and SMAD4, which hyperactivate the Wnt, MAPK, and PI3K signaling pathways [1, 10]. These cells exhibit significant heterogeneity and are categorized into consensus molecular subtypes (CMS) that influence their metabolic profile and interaction with the tumor microenvironment [11]. The therapeutic targeting of these cells is a cornerstone of modern oncology, utilizing a combination of systemic cytotoxic effects and precise molecular inhibition [1, 2]. Clinical management increasingly relies on the molecular characterization of these cells to identify actionable mutations, such as BRAF V600E or HER2 amplification, and to determine eligibility for immunotherapy based on microsatellite status [2, 3, 5]. Despite advancements, these cells present significant therapeutic challenges due to the rapid emergence of resistance and the potential for off-target toxicity to healthy intestinal epithelium [2, 6, 13].

Other names

Colon cancer cellRectal cancer cellColorectal adenocarcinoma cellMalignant colorectal cell

Drugs targeting colorectal tumor cells employ diverse mechanisms, including the inhibition of DNA synthesis and repair (antimetabolites and platinum agents), blockade of growth factor receptors such as EGFR to disrupt oncogenic MAPK/PI3K signaling, inhibition of angiogenesis by targeting VEGF, and the application of immune checkpoint inhibitors to reverse T-cell exhaustion [1, 2, 3, 5].